| Phase 19 trials |
|
Phase 1
|
NCT07128888 |
Nov 2025 → Jul 2026 overdue |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07144098 |
Aug 2025 → Jul 2026 overdue |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07119450 |
May → Aug 2025 |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT07141030 |
Apr → Oct 2025 overdue |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06670209 |
Oct 2024 → Mar 2025 overdue |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06554054 |
Apr → Dec 2024 overdue |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06548945 |
Apr → Aug 2023 |
morbid obesity |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05328726 |
Mar 2022 → Feb 2023 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06548997 |
Dec 2021 → Oct 2022 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06256536 |
Jul 2022 → Oct 2023 |
obesity disorder |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT06256523 |
Jun 2022 → Sep 2023 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT07055386 |
Aug 2025 → Jun 2026 overdue |
type 2 diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06737042 |
Feb 2025 → Feb 2026 |
obesity disorder |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06256549 |
Aug 2023 → Jul 2024 |
type 2 diabetes mellitus |
Gan and Lee Pharmaceuticals, USA |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT06256562 |
Jun 2023 → Jun 2024 |
obesity disorder |
Gan and Lee Pharmaceuticals, USA |
Completed
|
No outcome recorded
|
| Phase 39 trials |
|
Phase 3
|
NCT07622810 |
Sep 2026 → Dec 2027 expected |
obesity disorder |
Carnot Laboratories |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07628985 |
Sep 2026 → Oct 2027 expected |
type 2 diabetes mellitus |
Carnot Laboratories |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07493057 |
Apr 2026 → Nov 2027 expected |
obstructive sleep apnea syndrome |
Gan & Lee Pharmaceuticals. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07501832 |
Mar 2026 → Sep 2028 expected |
obstructive sleep apnea syndrome |
Gan & Lee Pharmaceuticals. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07292441 |
Jan 2026 → Sep 2027 expected |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07150975 |
Sep 2025 → Jun 2027 expected |
— |
Gan & Lee Pharmaceuticals. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06778967 |
Feb 2025 → Dec 2026 expected |
type 2 diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06777238 |
Jan 2025 → Aug 2026 overdue |
type 2 diabetes mellitus |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06728124 |
Dec 2024 → May 2026 overdue |
obesity disorder |
Gan & Lee Pharmaceuticals. |
Active not recruiting
|
No outcome recorded
|